Prescribing information

 

Cosentyx® (secukinumab) in rheumatology

Cosentyx is indicated alone or in combination with methotrexate, for the treatment of active PsA in adult patients when the response to previous DMARDs has been inadequate, for the treatment of active AS in adults who have responded inadequately to conventional therapy, and for the treatment of active nr-axSpA, with objective signs of inflammation, as indicated by elevated C-reactive protein and/or MRI evidence, in adults who have responded inadequately to NSAIDs

Evolving rheumatology services to support PsA patients in a new world:
Presented live at BSR 2021 on Wednesday 28th April

Hear from our speakers Dr Antoni Chan, Dr Kirsten Mackay, Julie Begum and Anusha Patel, who discussed:

  • The significance of early diagnosis, recognition, and treatment of the multiple manifestations of PsA
  • Current approaches to service delivery to support patients with PsA, taking into account the contribution of supplementary services, such as nurse-led clinics     
  • The impact of COVID-19 on rheumatology services and patients, and potential solutions for when we begin to emerge from the pandemic 

Watch Dr Kirsten Mackay’s presentation showing the management of two patient case studies

 

 

Watch the Q&A with the wider panel discussing ways of managing a PsA service during COVID-19

 

Take the next step

We’re here to support you with dedicated representatives up and down the country. Let us connect you with your local representative to discuss how you can get the most out of Cosentyx.

Or find out more using the links below...

Arrow with the text: Hear from the experts. Click image to find out more

Arrow with the text: Why Cosentyx in PsA? Click image to find out more

Arrow with the text: Why Cosentyx in axSpA? Click image to find out more

Arrow with the text: Discover our patient support programme. Click image to find out more

Arrow with the text: Can targeting IL-17A make the difference? Click image to find out more

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; BSR, British Society for Rheumatology; COVID-19, coronavirus disease 2019; DMARD, disease-modifying antirheumatic drug; IL, interleukin; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, psoriasis.

Rate this content: 
No votes yet
UK | August 2021 | 131657
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]